The All Wales Medicines Strategy Group (AWMSG) has issued a Statement of Advice for human normal immunoglobulin (Kiovig®) for immunomodulation in adults, and children and adolescents (0-18 years) in multifocal motor neuropathy.

The Advice states that in the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Kiovig®) cannot be endorsed for use within NHS Wales for this indication.